Core Insights - Tempus AI (TEM) is set to release its fourth-quarter 2025 results on February 24, 2026, after market close, with expectations of strengthened performance in 2026 due to strategic collaborations and product innovations [1] Financial Performance - Preliminary results indicate that revenues for the full year 2025 reached approximately $1.27 billion, marking an 83% year-over-year increase, with about 30% of this growth being organic [2] - Diagnostics revenues totaled around $955 million, reflecting a 111% year-over-year increase, driven by a 26% growth in oncology volume and a 29% increase in hereditary testing volume [3] - Data and applications revenues reached approximately $316 million, showing a 31% year-over-year growth, partly due to a 38% improvement in the Insights (data licensing) business [3][4] - The company achieved a Total Contract Value (TCV) of over $1.1 billion as of December 31, 2025, and reported positive adjusted EBITDA of $1.5 million in Q3 2025, a year-over-year improvement of $23.3 million [12] Strategic Collaborations - Tempus has entered a multi-year collaboration with Whitehawk Therapeutics, leveraging its proprietary dataset to enhance oncology research and clinical trial design [7][8] - The company initiated a research study with the Institute for Follicular Lymphoma Innovation, marking its first collaboration with a nonprofit to create a robust dataset for follicular lymphoma [11] Market Position and Challenges - Despite significant revenue growth, Tempus' stock price has declined by 32.9% in Q4, reflecting a broader negative sentiment in the AI medtech sector [6] - The stock currently trades at a price-to-book (P/B) ratio of 17.79X, which is above the industry average of 8.76X, raising valuation concerns [10][20] - The company continues to face challenges with GAAP losses due to stock-based compensation and amortization of acquired intangibles, limiting visibility into sustainable profitability [17][18] Future Outlook - The company is positioned as a high-growth leader at the intersection of AI and precision medicine, with strong operational momentum expected to continue into 2026 [21] - Investors are advised to maintain their positions in Tempus stock, which is currently rated as a Zacks Rank 4 (Sell) [22]

分组1 - 10x Genomics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and improved from a loss of $0.40 per share a year ago, resulting in an earnings surprise of +31.58% [1] - The company achieved revenues of $166.03 million for the quarter ended December 2025, slightly surpassing the Zacks Consensus Estimate by 0.01%, and showing a year-over-year increase from $165.02 million [2] - 10x Genomics has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance in earnings expectations [2] 分组2 - The stock has gained approximately 17.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for investors, as it reflects current consensus earnings expectations and any recent changes in those expectations [4] - The estimate revisions trend for 10x Genomics was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] 分组3 - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $142.23 million, and for the current fiscal year, it is -$0.88 on revenues of $609.12 million [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - Inspire Medical Systems reported quarterly earnings of $1.65 per share, exceeding the Zacks Consensus Estimate of $0.69 per share, and up from $1.15 per share a year ago, adjusted for non-recurring items [1] - The earnings surprise for this quarter was +137.65%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - The company posted revenues of $269.08 million for the quarter, surpassing the Zacks Consensus Estimate by 0.03%, and up from $239.72 million year-over-year, also exceeding revenue estimates in the last four quarters [3] 分组2 - The stock has underperformed the market, losing about 26.1% since the beginning of the year, while the S&P 500 gained 1.4% [4] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $212.59 million, and for the current fiscal year, it is $1.72 on $1 billion in revenues [8] - The Medical Info Systems industry is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [9]

分组1 - Omnicell reported quarterly earnings of $0.4 per share, missing the Zacks Consensus Estimate of $0.47 per share, and down from $0.6 per share a year ago, representing an earnings surprise of -15.34% [1] - The company posted revenues of $313.98 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.14%, and up from $306.88 million year-over-year [2] - Omnicell has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Omnicell shares up about 3.1% year-to-date compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.33 on revenues of $277.09 million, and for the current fiscal year, it is $1.80 on revenues of $1.21 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - KORU Medical Systems, Inc. (KRMD) experienced a significant stock price increase of 5.6% due to positive investor sentiment following FDA clearance for its FreedomEDGE infusion system, which enhances the delivery of large-volume subcutaneous drugs [1][2]. Financial Performance - The company is projected to report a quarterly loss of $0.02 per share, reflecting a year-over-year improvement of 33.3%. Expected revenues are $10.89 million, representing a 23.2% increase from the same quarter last year [3]. - The consensus EPS estimate for KORU Medical Systems has remained stable over the past 30 days, indicating no recent revisions in earnings estimates, which typically correlate with stock price movements [4]. Industry Context - KORU Medical Systems is part of the Zacks Medical Info Systems industry, where Claritev Corporation (CTEV) also operates. CTEV's stock closed 2.3% higher but has seen a decline of 19.9% over the past month [4].

Core Insights - TruBridge (TBRG) shares increased by 5.6% to close at $20.43, supported by higher trading volume compared to normal sessions, despite a 7.4% decline over the past four weeks [1][2] Company Performance - TruBridge has been recognized as one of Modern Healthcare's 2025 Best in Business, highlighting its commitment to rural and community healthcare, which includes helping providers recoup revenue and strengthen fiscal sustainability [2] - The company is projected to report quarterly earnings of $0.41 per share, reflecting a significant year-over-year increase of 720%, with expected revenues of $87.63 million, a slight increase of 0.3% from the previous year [3] Earnings Estimates and Stock Movement - The consensus EPS estimate for TruBridge has remained stable over the last 30 days, indicating that stock price movements may not sustain without changes in earnings estimate revisions [4] - TruBridge currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4]

Company Performance - Doximity (DOCS) closed at $38.96, down 3.56% from the previous trading session, underperforming the S&P 500's gain of 0.41% [1] - The company's shares have decreased by 8.66% over the past month, while the Medical sector lost 0.74% and the S&P 500 gained 0.38% during the same period [1] Upcoming Earnings - Doximity is set to release its earnings report on February 5, 2026, with an expected EPS of $0.44, reflecting a 2.22% decline compared to the same quarter last year [2] - Revenue is anticipated to be $181.03 million, which is a 7.37% increase from the prior-year quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, with revenue expected to reach $645.29 million, indicating increases of 9.86% and 13.13% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Doximity are crucial as they indicate shifts in near-term business trends, with positive revisions suggesting confidence in the company's performance [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity as 1 (Strong Buy), reflecting strong potential for outperformance [6] Valuation Metrics - Doximity has a Forward P/E ratio of 25.82, which is lower than the industry average of 27.99, indicating a valuation discount [7] - The company also has a PEG ratio of 1.36, compared to the industry average PEG ratio of 2.33, suggesting favorable growth prospects relative to its valuation [7] Industry Context - The Medical Info Systems industry, which includes Doximity, holds a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the strength of the Medical Info Systems sector [8]

Company Performance - Veeva Systems (VEEV) closed at $225.28, reflecting a +2.53% change from the previous day's closing price, outperforming the S&P 500 which gained 0.55% [1] - Prior to this trading session, VEEV shares had decreased by 1.53%, underperforming the Medical sector's gain of 0.19% and the S&P 500's gain of 0.71% [1] Upcoming Earnings - The upcoming earnings disclosure for Veeva Systems is anticipated, with projected earnings per share (EPS) of $1.92, indicating a 10.34% increase year-over-year [2] - Revenue is expected to reach $808.89 million, reflecting a 12.21% increase compared to the same quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates forecast full-year earnings of $7.93 per share and revenue of $3.16 billion, representing year-over-year changes of +20.15% and +15.13%, respectively [3] - Recent changes to analyst estimates for Veeva Systems are noted, as positive revisions indicate analysts' confidence in the company's performance and profit potential [3] Valuation Metrics - Veeva Systems is currently trading at a Forward P/E ratio of 27.72, which aligns with the industry average [6] - The company has a PEG ratio of 1.17, significantly lower than the industry average PEG ratio of 2.32 [6] Industry Context - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 157, placing it in the bottom 36% of over 250 industries [7] - The Zacks Industry Rank evaluates the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Industry Overview - The Medical Info Systems industry is rapidly expanding due to innovations in healthcare resource management, patient data handling, and integrated digital care delivery [1] - Companies in this industry develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Growth and Trends - The use of artificial intelligence (AI) in healthcare is projected to grow at a CAGR of 38.6% from 2025 to 2030, driven by demand for enhanced diagnostic accuracy and personalized medicine [2] - The global Smart Healthcare Products market was valued at $280.48 billion in 2024 and is expected to reach $796.36 billion by 2032, growing at a CAGR of 15.37% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Key Players - Doximity (DOCS) is a market leader in physician engagement, covering over 80% of U.S. doctors, with a subscription-based revenue model and a total addressable market of $18.55 billion [17] - 10x Genomics (TXG) develops products for analyzing biological systems, with a Zacks Consensus Estimate indicating a 72.4% improvement in earnings from 2024 to 2025 [21][22] - Omnicell (OMCL) focuses on medication management solutions and is expected to achieve a revenue CAGR of 2.8% from 2025 to 2027 [25] Financial Performance - The Medical Info Systems industry has underperformed the S&P 500 and the Zacks Medical sector, losing 7.7% over the past year compared to the sector's growth of 24.7% [11] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 4.65X, lower than the S&P 500's 5.65X and the sector's 2.35X [14] Cybersecurity Concerns - As healthcare systems become more digital, cybersecurity has emerged as a critical concern, with rising instances of ransomware and cyberattacks targeting healthcare organizations [7][8]

Core Viewpoint - IRHYTHM HLDGS (IRTC) shares experienced a 5% increase, closing at $163.24, following positive investor sentiment driven by preliminary fourth quarter operational highlights and expectations for strong revenue growth in 2025 [1][2]. Group 1: Company Performance - The company anticipates full year 2025 revenue to exceed the high end of its previous guidance of $740 million, attributed to record revenue unit volume in Q4 2025 [2]. - The Zacks Consensus Estimates project full year 2025 sales at $738.6 million, reflecting a year-over-year growth of 24.8% [2]. - For the upcoming quarterly report, the company is expected to post earnings of $0.02 per share, indicating a 100% year-over-year increase, with revenues projected at $200.3 million, a rise of 21.9% from the previous year [3]. Group 2: Earnings Estimates and Market Sentiment - The consensus EPS estimate for the quarter has been revised 0.6% higher in the last 30 days, suggesting a positive trend that typically correlates with stock price appreciation [4]. - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4]. - In the same industry, Clover Health Investments (CLOV) saw a 10.6% increase in its stock price, closing at $2.81, despite a -3.8% return over the past month [4].